[SCHEDULE 13G/A] Quantum Biopharma Ltd. Class B Subordinate Voting Shares SEC Filing

Rhea-AI Filing Summary

Malone Wealth Ventures LLC filed Amendment No. 4 to Schedule 13G on 10 July 2025, reporting a sizeable passive stake in Quantum Biopharma Ltd. (QNTM).

• Ownership level: The filing discloses beneficial ownership of approximately 19–20 % of QNTM’s common shares, equating to 689,421–735,148 shares depending on the section cited.
• Voting vs. dispositive power: Malone holds sole voting power over 103,601–109,765 shares but sole dispositive power over the full reported amount; no shared powers are reported.
• Filing status: The adviser filed on a Schedule 13G, indicating the position is held in the ordinary course of business and not with the intent to influence control of the issuer.
• Entity details: Malone Wealth Ventures LLC is a U.S.-based registered investment adviser; its clients ultimately benefit from dividends or sale proceeds, and no single client exceeds the 5 % threshold.
• Signatory: Kevin M. Malone, President & CEO, signed the certification.

The filing confirms that a professional asset manager has accumulated a near-20 % stake, potentially lending market confidence and increasing the free-float concentration, while remaining a passive investor. Investors should note the internal inconsistency between share counts (689,421 vs 735,148) and the consequent slight difference in reported ownership percentage (19.9 % vs 19.4 %).

Positive

• Near-20 % ownership by a registered investment adviser demonstrates meaningful institutional confidence in QNTM.
• Passive 13G filing signals no immediate governance disruption, reducing activist risk for current management.

Negative

• Inconsistent share totals (689,421 vs 735,148) within the filing may create uncertainty about the exact stake size.
• Concentration risk: A single adviser controlling ~20 % could amplify volatility if the position is reduced later.

Insights

Portfolio Manager

TL;DR: Passive 13G shows Malone holds ~20 % of QNTM, signalling confidence without control ambitions.

The disclosure that an SEC-registered investment adviser owns nearly one-fifth of Quantum Biopharma’s outstanding shares is constructive for sentiment. A passive 13G suggests Malone views the position as an investment rather than an activist platform, limiting governance disruption risk. Concentrated ownership can improve share-price stability and facilitate future capital raises by demonstrating institutional backing. However, the discrepancy between 689 k and 735 k shares raises minor data-quality concerns that investors may wish to clarify with the company or filer.

Corporate Governance Specialist

TL;DR: Large passive stake alters ownership landscape but avoids control contest.

Crossing the 5 % threshold—let alone approaching 20 %—is significant for governance visibility. Because Malone filed under Rule 13d-1(b)/(c) rather than 13D, it disclaims any intent to influence management or board composition. This lowers the probability of activist campaigns yet concentrates voting power in a single advisory firm. Shareholders should monitor future filings for status changes (13D switch or ownership swings). The inconsistent share count within the same amendment slightly weakens disclosure precision but does not change the material fact that Malone is now a key stakeholder.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

07/10/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 109,765.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 689,421.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

689,421.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

19.9 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 735148
(b)	Percent of class: 19.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 103601
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 735148
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. No individual client is known to have such interest relating to more than five percent of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President & CEO
Date:	07/10/2025

FAQ

How many Quantum Biopharma (QNTM) shares does Malone Wealth Ventures own?

The filing lists between 689,421 and 735,148 shares, representing roughly 19–20 % of the class.

Is Malone Wealth Ventures an activist investor in QNTM?

No. The stake is disclosed on Schedule 13G, indicating a passive investment with no intent to influence control.

What voting power does Malone Wealth Ventures have over QNTM shares?

Malone reports sole voting power over about 104–110 thousand shares and sole dispositive power over the full stake.

Why is there a discrepancy in the share count within the same 13G filing?

The document shows two figures (689,421 vs 735,148). The filer did not explain the difference, so investors may seek clarification.

Who signed the Schedule 13G on behalf of Malone Wealth Ventures?

Kevin M. Malone, President & CEO, signed and certified the filing on 10 July 2025.